Incyte (INCY) Total Non-Current Liabilities (2013 - 2026)
Incyte's (INCY) quarterly Total Non-Current Liabilities came in at $1.4 billion in Q2 2026, down 4.54% YoY from $1.5 billion in Q2 2025, and down 11.7% on a QoQ basis from $1.6 billion in Q1 2026.
Incyte (INCY) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Incyte (INCY) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.4 billion in Q2 2026.
- Quarterly Total Non-Current Liabilities fell 4.54% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (down 4.54% YoY) and the FY2025 annual result came in at $1.6 billion, down 11.15% from the prior year.
- Total Non-Current Liabilities declined to $1.4 billion in Q2 2026, from $1.6 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.9 billion in Q1 2025 to a low of $987.0 million in Q1 2022.
- A 5-year average of $1.4 billion and a median of $1.4 billion in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 38.92% — and 2026, when it slipped 16.61%.
- Tracing INCY's Total Non-Current Liabilities over 5 years: stood at $1.3 billion in 2022, then gained by 10.28% to $1.4 billion in 2023, then rose by 28.93% to $1.8 billion in 2024, then decreased by 11.15% to $1.6 billion in 2025, then declined by 13.63% to $1.4 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $1.4 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 1.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Bn |
| Mar 31, 2026 | 1.59 Bn |
| Dec 31, 2025 | 1.63 Bn |
| Sep 30, 2025 | 1.51 Bn |
| Jun 30, 2025 | 1.47 Bn |
| Mar 31, 2025 | 1.91 Bn |
| Dec 31, 2024 | 1.83 Bn |
| Sep 30, 2024 | 1.67 Bn |
| Jun 30, 2024 | 1.51 Bn |
| Mar 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 1.29 Bn |
| Jun 30, 2023 | 1.29 Bn |
| Mar 31, 2023 | 1.15 Bn |
| Dec 31, 2022 | 1.29 Bn |
| Sep 30, 2022 | 1.11 Bn |
| Jun 30, 2022 | 1.03 Bn |
| Mar 31, 2022 | 987.02 Mn |
| Dec 31, 2021 | 956.35 Mn |
| Sep 30, 2021 | 836.39 Mn |